UNSPSC 51142408: Frovatriptan

This classification denotes a serotonin agonist with the molecular formula C14H17N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier H82Q2D5WA7, chemically known as 6-methylamino-6,7,8,9-tetrahydro-5h-carbazole-3-carboxamide but generally known as frovatriptan, which bears US NIH Compound Identifier 77992. European Medicines Agency schedules Frovatriptan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07817MIG.

UNSPSC 51142408 Frovatriptan is a Commodity code that nominally describes a specific migraine treatment, but recent state and local solicitation activity shows little direct demand for the drug itself. Instead, the opportunities tagged to this code reflect a broader landscape of pharmaceutical procurement, including generic multi-source drugs, over-the-counter products, and emergency medical supplies such as naloxone and drug deactivation systems. State and local governments are buying these products through competitive bidding processes managed by county health departments, state health agencies, and cooperative purchasing alliances, with vendors required to meet FDA compliance, Good Manufacturing Practices certification, Drug Supply Chain Security Act (DSCSA) adherence, and specific insurance and employee-eligibility verification requirements.

The issuing-body mix spans county health departments (Seminole County, Florida), state health agencies (Texas Health and Human Services Commission), and multistate cooperative purchasing entities (Minnesota Multistate Cooperative Purchasing Alliance, which draws participants from multiple states including Oregon). Recent opportunities include Seminole County's competitive bid (IFB) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, posted June 30, 2026, due July 26, 2026; the Texas HHS Commission's Request for Information on direct-to-manufacturer prescription programs, posted April 3, 2026; and MMCAP's Request for Proposal for generic pharmaceuticals and OTC products across multiple state and local facilities, posted January 20, 2026, with proposals due March 26, 2026. Geographic activity centers on Florida, Texas, Minnesota, and Oregon, though the cooperative purchasing model suggests broader regional participation. Vendors pursuing this code should recognize that the actual pharmaceutical product—frovatriptan by name—is not the focus of current state and local solicitation, making the code a weak signal for business development purposes relative to the broader generic and OTC pharmaceutical categories it nominally sits within.